Squarepoint
MAZE

Squarepoint’s Maze Therapeutics MAZE Stock Holding History

Squarepoint’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Buy
+13,612
New +$601K ﹤0.01% 3471

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Squarepoint's MAZE Position: Q1 2026 in Review

Squarepoint opened a new position in Maze Therapeutics (MAZE) in Q1 2026: 13,612 shares worth $406K. The stake represents ﹤0.01% of the portfolio and ranks #3471 among its holdings.

165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Squarepoint held 13,612 shares of Maze Therapeutics worth $406K as of Q1 2026.
  • Maze Therapeutics was a new Squarepoint position in Q1 2026.
  • Maze Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3471 holding.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.